India, Nov. 5 -- Sun Pharmaceutical Industries Ltd. delivered on its quarterly profit in July-September 2025, helped by strong demand for its drugs in India. Operational profitability, however, dipped.

Net profit of India's largest drugmaker rose 2.6% over the year-ago period to Rs.3,118 crore in the three months ended 30 September, on revenue that increased 8.9% year-on-year to Rs.14,478 crore, according to an exchange filing on Wednesday (5 November 2025).

One basis point is one-hundredth of a percentage point.

That quarterly performance came on the back of 11% growth in sales in India - its largest revenue-generating region.

Sun Pharma has been focusing on strengthening its portfolio of innovative drugs in dermatology, oncology and...